Important notice regarding the PERSIST-1 and PER... - MPN Voice

MPN Voice

10,340 members14,250 posts

Important notice regarding the PERSIST-1 and PERSIST-2 drugs trials using Pacritinib

Mazcd profile image
MazcdPartnerMPNVoice
0 Replies

CTI BioPharma, the licence holders for Pacritinib, has requested all patients stop taking pacritinib after it received information from the U.S. Food and Drug Administration (FDA) regarding PERSIST-1 and PERSIST-2 drug trials.

If you are enrolled on the PERSIST-1 and PERSIST-2 trials and have been prescribed Pacritinib you should have been contacted by your trial team and given instructions regarding stopping the Pacritinib.

Hopefully there will still be the opportunity to use this drug in the future as there was clear evidence of benefit for many patients but this decision has been taken with regard to balance of risks.

Written by
Mazcd profile image
Mazcd
Partner
To view profiles and participate in discussions please or .

You may also like...

Great group of videos

Antonio Patients Conference...

Questions about AEs on Interferons w.r.t. liver enzymes

of 75 patients there was “transaminitis at grade 1 in 6 patients (8%) and grade 2 in 3 patients...

New Patient with ET for 18 years but developed some odd symptoms!

do not know whether is related to the drug or not?!! I have been in and out of GP/Hospital for the...

Thoughts on MAJIK trial outcomes

perspective, was: 1. Of the drugs available, HC provides the best outlook for ET patients for...

Clinical Trial Exceed ET

are your side effects? How long have you been on this drug? Do you have PV, ET, or other? What...